statistiche ricercatore

PICCIN, Daniela

Distribuzione geografica

Continente	#
NA - Nord America	1462
EU - Europa	452
AS - Asia	239
Totale	2153

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	1459
CN - Cina	181
DE - Germania	140
UA - Ucraina	119
GB - Regno Unito	55
TR - Turchia	52
SE - Svezia	30
IT - Italia	28
FI - Finlandia	27
BE - Belgio	19
RU - Federazione Russa	19
FR - Francia	9
CA - Canada	3
IE - Irlanda	2
IN - India	2
IR - Iran	2
NL - Olanda	2
BD - Bangladesh	1
CZ - Repubblica Ceca	1
KZ - Kazakistan	1
RO - Romania	1
Totale	2153

Salva come PNG Salva come JPEG

Città	#
Woodbridge	277
Fairfield	164
Jacksonville	139
Chandler	131
Houston	129
Ann Arbor	99
Seattle	69
Wilmington	60
Ashburn	55
Beijing	54
Cambridge	54
Addison	47
Izmir	44
Nanjing	38
Princeton	27
Milan	23
Boardman	21
San Diego	21
Brussels	19
Dearborn	16
Shenyang	15
Kunming	11
Guangzhou	8
Hebei	8
Jiaxing	8
Nanchang	8
Jinan	7
Changsha	6
Norwalk	6
San Mateo	6
Leawood	5
Mountain View	5
Redwood City	5
Des Moines	4
Falls Church	4
Tianjin	4
Washington	4
Hangzhou	3
Monmouth Junction	3
Montréal	3
Munich	3
Ardabil	2
Augusta	2
Dublin	2
Hefei	2
Helsinki	2
New York	2
Philadelphia	2
Taizhou	2
Verona	2
Almaty	1
Bremen	1
Changchun	1
Delhi	1
Dhaka	1
Ferrara	1
Hanover	1
Jinhua	1
Mcallen	1
Messina	1
Mumbai	1
Ningbo	1
Paris	1
Shanghai	1
Yellow Springs	1
Zhengzhou	1
Totale	1647

Salva come PNG Salva come JPEG

Nome	#
Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism	136
Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression.	129
Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.	129
Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion.	128
Proteasomes and RARS modulate AIMP1/EMAP II secretion in human cancer cell lines.	106
null	106
Somatostatin receptor subtype 1 selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line.	102
miR-15a and miR-16-1 down-regulation in pituitary adenomas	98
Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas.	97
SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma	96
Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT.	95
An in vivo OctreoScan-negative adrenal pheochromocytoma expresses somatostatin receptors and responds to somatostatin analogs treatment in vitro	90
Role of complex Cdk4/Cyclin D1 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro	78
Antiproliferative effects of somatostatin analogs in pituitary adenomas	77
Somatostatin receptor subtype 1 selective activation in human growth hormone- and prolactin-secreting pituitary adenomas: effects on cell viability, growth hormone and prolactin secretion.	77
SHP-1 restrains cell proliferation in human medullary thyroid carcinoma	76
Multiple somatostatin receptor subtypes activation reduces cell viability in non-functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion	71
Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin A secretion and on cell viability in human non-functioning pituitary adenomas in vitro	64
Selective Cyclo-oxygenase 2 inhibitors revert chemoresistance In Medullary thyroid carcinoma by a mechanism mediated by P-gp and PGH2	61
Chemoresistance of Medullary thryroid carcinoma cells is reversed by COX-2 inhibitors in vitro through a PGE2-dependent mechanism	59
Role of complex Cyclin D1/Cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro.	58
Somatostatin inhibits a medullary thyroid carcinoma cell line growth by activating SHP-1	58
Somatostatin analogs in vitro effects in a growth hormone-releasing hormone (GHRH)-secreting bronchial carcinoid	58
SSTR subtypes expression pattern influences the antiproliferative effects of somatostatin and lanreotide on human medullary thyroid carinomas in vitro	53
Somatostatin differentially influences proliferation and gene expression by modulating SHP-1 and cAMP pathways in a human medullary thyroid carcinoma cell line	53
Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro	11
Totale	2166

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	4621
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	4621

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2018/2019	348	6	6	10	14	15	1	42	6	27	47	60	114
2019/2020	510	76	16	20	61	42	61	43	54	37	54	39	7
2020/2021	287	34	29	8	33	12	29	11	32	6	34	49	10
2021/2022	330	10	41	31	6	18	12	17	11	10	21	33	120
2022/2023	288	28	24	24	35	36	46	28	17	33	4	13	0
Totale													2166